Anti-CD3 mAb can modulate graft rejection and attenuate autoimmune diseases but their mechanism(s) of action remain unclear. CD8+ T cells with regulatory function are induced in vitro by Teplizumab, a humanized anti-CD3 antibody and inhibit responses of autologous and allogeneic T cells. They inhibit CD4+ T-cell proliferation by mechanisms involving TNF and CCL4, and by blocking target cell entry into G2/M phase of cell cycle but neither kill them, nor compete for IL-2. CD8+ Treg can be isolated from peripheral blood following treatment of patients with Type 1 diabetes with Teplizumab, but not from untreated patients. The induction of CD8+ Treg by anti-CD3 mAb requires TNF and signaling through the NF-κB cascade. The CD8+ Treg express CD25, glucocorticoid-induced TNF receptor family, CTLA-4, Foxp3, and TNFR2, and the combined expression of TNFR2 and CD25 identifies a potent subpopulation of CD8+ Treg. These studies have identified a novel mechanism of immune regulation by anti-CD3 mAb and markers that may be used to track inducible CD8+ Treg in settings such as chronic inflammation or immune therapy.
Adaptive or inducible (iTreg) have been described in humans and in mice in settings such as immunization, tumor progression, or following infection. These cells have been found in the spleen, thymus, and in the peripheral blood of healthy subjects, and they were inhibitory to autologous cells that were activated with a variety of stimuli 1–3. Walker et al. described the expression of Foxp3, a transcription factor associated with Treg and acquisition of suppressive activity in human CD4+CD25+ T cells activated with anti-CD3 mAb OKT3 4. Pathways for differentiation of T cells with regulatory function have been described that are dependent on TGF-β, the expression of Foxp3, and suppression of retinoic acid-related orphan receptor γt 5. Many studies have focused on subpopulations of CD4+CD25+ T cells but others have described inducible CD8+ Treg (iCD8+ Treg) in mice and humans in chronic viral infections or allograft tolerance that can inhibit responses by direct cytotoxicity to targets or by other mechanisms 6–13.
Immune therapies may induce and/or improve the function and survival of Treg. Intravenous Ig has been shown to increase the suppressive function of CD4+CD25+ T cells in vitro14. Anti-TNF therapy was reported to increase the number of mucosal Foxp3+CD4+CD25+ Treg in children with inflammatory bowel disease 15. Anti-CD154 mAb was also shown to prevent diabetes in the NOD mouse model by inducing non-deletional tolerance and expanding Treg 16. Rapamycin monotherapy of patients with Type 1 diabetes mellitus (T1DM) who received islet allotransplants resulted in improved potency of naturally occurring CD4+CD25+ Treg although the number of the Treg did not increase 17. In a study of human islet allograft recipients with T1DM treated with tacrolimus and sirolimus, Hering et al. reported that humanized anti-CD3 mAb (Teplizumab, formerly hOKT3γ1(Ala-Ala)) increased the number and function of CD4+CD25+ T cells 18. However, the cause for the appearance of such cells was not clear since the therapy involved a combination of drugs.
In the previous studies, we reported that treatment of patients with new onset T1DM with Teplizumab attenuated the loss of insulin production during the first years of the disease 19, 20. The humanized mAb is non-FcR binding but does cause activation of T cells in vitro and in vivo. Clinical responders to drug treatment were identified by a relative increase in the proportion of circulating CD8+ T cells. It has been shown that the mAb was more mitogenic for CD8+ T cells than for CD4+ cells 21, 22. However, when CD8+ T cells were depleted from cultures, CD4+ T cells were shown to proliferate in response to anti-CD3 mAb, suggesting that the CD8+ T cells, particularly those that expressed CD25 following culture with anti-CD3 mAb were inhibitory to the CD4+ cells 22. However, the mechanism whereby the mAb induced these regulatory cells and functional evidence for the induction of these cells in patients was not available.
Herein, we show that treatment of patients with new onset T1DM may induce iCD8+ Treg in vivo. In vitro-induced CD8+ Treg have phenotypic features characteristic of other Treg including the expression of Foxp3, CTLA-4, and glucocorticoid-induced TNF receptor family (GITR), but their mechanism of inhibition is independent of TGF-β or IL-10. As with other Treg populations, they can inhibit allogeneic CD4+ effector cells. The induction of these cells by anti-CD3 mAb is dependent on TNF, is associated with upregulation of TNFR, and requires signaling through NF-κB. In addition, TNFR2 expression identifies the most potent regulatory CD8+ cells. Thus, our studies identify a new mechanism for generation of human iCD8+ Treg by TCR engagement.
Culture of normal human PBMC with Teplizumab induces CD8+ Treg
In our previous studies, we found that hOKT3γ1(Ala-Ala) (Teplizumab) induced CD8+ T-cell proliferation in vitro and that the activated cells inhibited proliferative responses to a nominal antigen, tetanus toxoid 22. Our previous studies had suggested that following culture with the anti-CD3 mAb, the CD8+CD25+ subpopulation was more inhibitory than CD8+CD25− cells. In this study, we tested the ability of CD8+ T cells cultured with anti-CD3 mAb, to inhibit polyclonal CD4+ T-cell responses to staphylococcal enterotoxin B (SEB) and confirmed that CD8+CD25+ T cells were more potent inhibitors compared with CD8+CD25− T cells (Fig. 1A). In data from 12 independent experiments, the CD8+CD25+ T cells isolated from Teplizumab treated cultures showed 44.2±4.4% inhibition compared with 28.7±4.4% inhibition by CD8+CD25− cells from the same cultures (p=0.0005), or to −0.3±3.3% inhibition by CD8+ cells that were cultured with control IgG (p=0.0005). CD25 was not detectable on CD8+ T cells cultured in control Ig. To exclude the possibility that the inhibitory effect of the CD8+ T cells was due to carry over of anti-CD3 mAb that had been bound to membranes of these cells, we added Teplizumab to control CD8+ T cells at tenfold concentrations from 1 ng/mL to 1 μg/mL in the presence of CD4+ effector cells and SEB. No inhibition of proliferation to SEB was seen in the presence of anti-CD3, suggesting that coating with anti-CD3 mAb per se was not responsible for the inhibitory effect (data not shown).
We then tested whether the iCD8+ Treg would inhibit allogeneic CD4+ T cells or whether their inhibitory function was limited to autologous cells. Analysis of pooled data with a total of six allogeneic donors tested in three separate experiments showed that CD8+CD25+ T cells inhibited proliferation by 48.1±3.0% (p<0.05 by ANOVA), suggesting that autologous MHC recognition is not required for the regulatory function (Fig. 1B and C).
Phenotype of iCD8+ Treg
We characterized the phenotype of the CD8+CD25+ T cells following culture with the anti-CD3 mAb (Fig. 2A). On day 5 of culture, Foxp3 was expressed in 2–10% of CD8+ T cells but about 30% of the CD8+CD25+ T cells. The Foxp3+CD8+ T cells expressed low levels of CD127 as well as CTLA-4 and GITR. Control IgG-treated CD8+ T cells were Foxp3−, CD25−, CD127+, GITR−. The CD8+Foxp3+ cells did not produce TGF-β or IL-10 before (Fig. 2B) or after (Fig. 2C) activation with PMA and ionomycin but did express low levels of IFN-γ and TNF. The relative expression of this transcription factor was lower on CD8+ T cells than on CD4+CD25+ T cells that had been cultured for an equivalent period of time with anti-CD3 mAb (Fig. 2D).
Treatment with Teplizumab induces iCD8+ Treg in patients with T1DM
Our previous finding that clinical responses to anti-CD3 mAb correlated with an increased number of circulating CD8+ T cells raised the possibility that the mAb might induce iCD8+ Treg in patients with T1DM who had been treated with the mAb. We first tested whether iCD8+ Treg may be induced in vitro from PBMC of T1DM patients. We cultured PBMC with anti-CD3 or control Ig for 5 days and isolated CD8+ T cells by negative magnetic selection. We then tested the inhibitory capacity of these cells to CD8-depleted allogeneic PBMC activated with SEB. Figure 3A shows that anti-CD3-treated CD8+ cells from patients were also able to inhibit proliferation.
To test directly whether administration of Teplizumab induces iCD8+ Treg in vivo, we isolated CD8+ T cells from patients with new onset Type 1 diabetes who were enrolled in clinical trials with Teplizumab and tested the ability of these cells to inhibit proliferative responses of allogeneic CD8-depleted PBMC to SEB. We used cryopreserved target cells from the same allogeneic donor to test the effects of the patients' CD8+ cells in order to reduce the variability in anti-SEB responses between the patients. The CD8+ cells were negatively isolated from PBMC isolated from patients before and after Teplizumab treatment, or from patients who were not treated with the drug but in whom blood samples were obtained at the same time points. Here, we tested total CD8+ T cells without further sorting based on the CD25 expression since in individuals not treated with anti-CD3, there were very low numbers of CD8+CD25+ T cells. The inhibition shown in Fig 3B and C reflects the percentage reduction in proliferation when CD8+ cells from the second draw (or after treatment) were added to the cultures, compared with CD8+ cells from the first draw (before treatment). It shows that CD8+ T cells isolated from patients on day 14 inhibited allogeneic CD4+ T cells proliferation in response to SEB by 9.23±2.83%, whereas cells from the untreated control group inhibited proliferation of the same allogeneic responding CD4+ T cells by 1.54±0.95% (p<0.05). Five out of ten drug-treated patients showed the level of inhibition that was 3 SD greater than the level of inhibition seen in the control group. These data suggest that administration of anti-CD3 mAb resulted in the appearance of CD8+ T cells with inhibitory function in the peripheral blood of some T1DM patients.
iCD8+ Treg inhibit proliferation of target T cells
The inhibitory effect of CD8+ T cells might be due to a direct competition with CD4+ cells for IL-2. This was not the case, since the inhibitory effect of the CD8+ Treg was not reversed by adding IL-2 to the cocultures (data not shown). A direct cytotoxic effect of Treg on target cells has been suggested as a mechanism of inhibition by human CD8+ Treg 23–25. We therefore measured apoptotic and necrotic CD4+ T cells after 72 h incubation in the presence of iCD8+CD25+ T cells from cultures with Teplizumab and SEB. Figure 4A shows that the SEB increased the proportion of dead CD4+ cells due to activation but the anti-proliferative properties of CD8+ Treg were not associated with increased killing, since addition of the CD8+ Treg did not increase the proportion of apoptotic (YO+) or necrotic (PI+) CD4+ T cells.
In addition, when measured by intracellular cytokine staining, the CD8+ T cells did not block secretion of cytokines such as TNF or IFN-γ by CD4+ T cells in response to SEB (Fig. 4B). Instead, using cell cycle analysis, we found that progression of CD4+ responder cells into G2/M phases, in response to SEB were inhibited when CD8+CD25+ Treg were added to cultures (Table 1).
Table 1. Cell cycle analysis of SEB-responding CD4+ T cells after 72 h incubation with sorted CD8+ T cells pretreated with either Teplizumab or control human IgGa)
a) Cells were gated as CD4+Ki67+, and percent of these cells in each phase based on the DNA content is shown for three separate experiments.
Our previous data had shown that either cell contact and/or close proximity to target cells were required for the regulatory function of iCD8+ Treg, whereas studies by others have suggested a number of soluble mediators of inhibition. The inhibition of anti-SEB responses could not be transferred with supernatants from the CD8+ iTreg (data not shown). Since it was still possible that soluble factors produced by the iCD8+ Treg could be responsible for the inhibition by working at high concentrations in close proximity, we used neutralizing antibodies to candidate mediators of Treg function, such as CCL4 11, IL-10 26, 27, and others. Figure 4C shows that anti-TNF (in five out of five experiments) and anti-CCL4 (in four out of four experiments) showed significant effects (12.9±2.3% (p=0.005) and 14.4±3.8% (p=0.032)) in partially reversing the inhibitory action of the iCD8+ Treg, respectively. This suggests that CCL4 and TNF may play a partial role in the cytostatic effect of the iCD8+ Treg.
iCD8+ Treg require TNF for induction
TNF is found in the supernatants of PBMC cultured with modified anti-CD3 mAb, and increased levels of TNF in circulation had been identified in patients with T1DM during treatment with Teplizumab 22. We therefore tested the role of this cytokine for the development of the iCD8+ Treg. We added neutralizing anti-TNF antibody to normal human PBMC cultures in the presence of Teplizumab and studied proliferation, activation, and induction of CD8+ Treg. Anti-TNF dramatically abrogated proliferation of CD8+ T cells in response to anti-CD3, whereas neutralization of another TNF family member, FasL did not (Fig. 5A). Anti-TNF mAb prevented upregulation of CD25 on CD8+ T cells (Fig. 5B), and prevented induction of regulatory function (Fig. 5C). The addition of normal human IgG at the equivalent molar concentrations as anti-TNF mAb (80 μg/mL) had no discernable effect on the expression of CD25 or the induction of CD8+ Treg. To test which cells were the major producers of TNF, we stained anti-CD3-activated PBMC for intracellular TNF and counted absolute numbers of TNF producers per 30 000 total PBMC. As shown in Fig. 5D, although non-T cells contributed to TNF production, the major cell populations secreting TNF in response to anti-CD3 were CD4+ and CD8+ T cells.
TNF activates several signal transduction pathways, the major of which is that of NF-κB 28. We therefore tested whether blockade of the NF-κB pathway by sulfasalazine, or with Bay 11-7082, an inhibitor of IKK phosphorylation, 29–33 affected the generation of CD8+ Treg from PBMC. Both reagents blocked the induction of the activated cell phenotype and inhibitory function (Fig. 6A). The effects of TNF are mediated via two distinct receptors, TNFR1and TNFR2. We therefore stained PBMC for both receptors and compared the level of their expression after incubation of the cells with anti-CD3 or control human IgG. Figure 6B (upper panels) shows that anti-CD3 treatment strongly upregulated expression of TNFR2, whereas TNFR1 levels were relatively low. TNFR2 expression only partially overlapped with that of CD25 (Fig. 6B, lower panels). After culture with anti-CD3 mAb, 9.5±1.5% (n=6) of CD8+ T cells were TNFR2+CD25+, and these cells were the major subset of CD8+ T cells that expressed Foxp3 (Fig. 6C). We postulated, therefore, that TNFR2 may serve as a marker for a more potent subpopulation of CD8+ Treg. To address this question, we sorted CD8+ T cells that had been cultured with anti-CD3 mAb based on the TNFR2 expression and compared their potency as regulators. Figure 6D shows that both CD8+CD25+ and CD8+CD25− cells were better inhibitors of proliferation if they coexpressed TNFR2, suggesting that TNFR2 is a marker of human iCD8+ Treg.
The mechanism(s) whereby modified anti-CD3 mAb affect human T-cell responses are poorly understood. Preclinical and clinical studies from our group and others have indicated that T-cell depletion alone is an unlikely mechanism. These and other studies have suggested that the mAb may induce Treg 13, 22, 34. However, the identity, function, and way in which iTreg are induced have not been clear.
Regulatory CD8+ T cells have been described in a number of immune settings 35. Cantor and colleagues proposed that CD8+ Treg, restricted by the minor Class I Qa-1 antigen may play a role in the prevention of autoimmune responses by activated CD4+ T cells. 12, 36. Likewise, Jiang and coworkers described human CD8+ Treg that inhibit alloresponses and were restricted by Class I human MHC molecule HLA-E presenting TCR Vbeta-derived peptides 37, 38. Our data would suggest that the regulation of CD4+ responses by the iCD8+ Treg induced by anti-CD3 mAb is not HLA-restricted since the responses of allogeneic CD4+ cells were also inhibited. In tolerant heart allograft recipients, Suciu-Foca and coworkers have described regulatory CD8+ T cells that interact with APC via ILT3 and ILT4 39. Similarly, we have found that APC are needed to induce CD8− Treg, but their role in mediating suppression has not been studied.
We have found that circulating CD8+ T cells isolated from patients after treatment with anti-CD3 mAb may have regulatory function ex vivo. To our knowledge, this is the first report showing functional human CD8+ Treg in vivo after administration of anti-CD3 mAb. CD8+ T cells isolated from patients after anti-CD3 mAb treatment inhibited proliferation of allogeneic CD4+ T cells activated with superantigen. The degree of inhibition was less than we observed with CD8+ T cells that were cultured with the mAb in vitro, which cannot be explained by differences in T cells from healthy control subjects and patients with T1DM since CD8+ Treg from the patients could be equally induced in vitro (Fig. 3A). One possibility is that the Treg induced in vivo were diluted in the total CD8+ fraction of cells that was tested. We did not study the function of other phenotypes of T cells, such as CD4+CD25+ cells that have been shown to have regulatory activity and have been reported to be induced by the anti-CD3 mAb, but we have not found an increase in the proportion of these cells in patients treated with Teplizumab unlike a previous report by Hering et al. which included subjects treated with multiple immunologics 18
Joosten et al. reported that CD8+ T cells inhibited the proliferative responses of CD4+ cells to antigen through a mechanism that required CCL4 and LAG3 11. Our previous studies, which suggested that cell contact was required for inhibition, did not exclude an effect of a soluble mediator that might be inhibitory at high concentrations in a local environment. Indeed, our cytokine neutralization studies agree with these previous findings and suggest that there is a contributory role for TNF and CCL4 although the results from blockade of each of these molecules were modest.
TNF is responsible for induction of the CD8+ Treg since the effects of anti-CD3 mAb on functional responses of T cells were neutralized by anti-TNF mAb. The importance of TNF for the induction of human CD8+ Treg is interesting in the light of recent reports by Chen et al., demonstrating that TNF is needed for induction of murine CD4+CD25+ Treg, and that TNFR2 in both mouse and human serves a marker of more potent CD4+ Treg 40. Our data reported here are in agreement with these observations, since TNFR2 was the major TNFR on T cells, TNFR2+ cells are the major expressors of Foxp3, and are more potent inhibitors of anti-SEB responses. Interestingly, in human CD4+ Treg coexpression of CD25 and TNFR2 identifies a potent subpopulation of Treg 41–44, which is in agreement with our studies, but we also found that TNFR2 is seemingly a more important marker than CD25 on CD8+ Treg.
Anti-CD3 upregulates both CD25 and TNFR2, however, the CD25+TNFR2− cells represent a relatively minor subpopulation, and hence the majority of CD25+ cells are TNFR2+. On the contrary, CD25− population consists of comparable numbers of TNFR2+ and TNFR2– cells. Consistent with the notion of relative potency of TNFR2+ and/or CD25+ cells is our finding that the Foxp3+CD8 cells are found almost exclusively in the TNFR2+ cells (Fig. 6C).
In vitro, TNF appears to be produced by T cells, but a role for APC-derived TNF cannot be excluded 22. This possibility seems particularly attractive in the light of a recent report, showing that TNFR2 is activated by the membrane-bound TNF 45. Interestingly, our findings are in conflict with the findings in patients with Crohn's disease, in which anti-TNF treatment increased mucosal CD4+CD25+(Foxp3+) T cells. This discrepancy may reflect the different culture conditions since we analyzed the role of TNF in the setting of TCR stimulation 15. In addition, it is possible that there is a unique role for TNF in the setting of Crohn's disease and the inflammatory setting in the gut.
The signs and symptoms of “cytokine release syndrome” associated with anti-CD3 administration and other biologics have been attributed to the actions of several cytokines including TNF 46. These new findings suggest that both beneficial and harmful effects may arise from the actions of this cytokine. Therefore, careful consideration of dosing of the anti-CD3 mAb is needed to avoid the systemic toxicities while maintaining the immunologic effects of TNF.
We propose that iCD8+ Treg may be a common occurrence in humans in the settings of inflammation, TCR activation, and TNF production. Our studies show that the effect of these cells is to inhibit the division of CD4+ T cells which may serve to limit expansion of antigen specific cells. The duration of the CD8+ Treg following anti-CD3 mAb is unknown, but the changes in CD4/CD8+ T-cell ratio that had identified clinical responders to drug treatment in our initial studies persisted beyond three months 19. Holding CD4+ cells at bay for an extended period of time may allow other inflammatory signals to resolve and avoid propagation of cells with autoreactive potential.
Materials and methods
Human subjects and samples
The studies were done with PBMC from healthy volunteers were received from the New York Blood Center (Long Island City, NY) and, in selected experiments, PBMC collected from patients with Type 1 diabetes, participating in open label portions of two clinical studies: “Study 1” 20, 22 or an open label segment of Protégé (Clinicaltrials.gov: NCT00385697). In addition, samples were collected from patients with Type 1 diabetes for >2 years. The patients were between the ages of 8–30. Teplizumab-treated subjects received a 12–14 day course of the mAb treatment as described previously 19, 20. Control samples, from patients with T1DM who did not receive Teplizumab, were collected at the same time intervals. Isolated PBMC were stored in liquid nitrogen until use. The protocols received Institutional Review Board approval and informed consent was obtained from all participants or their guardians.
Culture with anti-CD3 mAb and sorting of CD8+ T cells
PBMC were separated using Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden). The cells were cultured in AIM-V medium (Invitrogen, Grand Island, NY, USA) at 1×106/mL with 4 μg/mL Teplizumab hOKT3γ1(Ala-Ala) 47, or with normal human IgG (Sigma, St. Louis, MO, USA). To block NF-κB signaling, Sulfasalazine (Sigma) or Bay 11-7082 (Calbiochem) were added at the final concentration 2 mM or 2.5 μM, respectively, during the primary cultures of PBMC with anti-CD3 mAb 30, 33, 32. In preliminary studies, we determined the maximal concentration of Bay 11-7082 that would not affect CD8+ T-cell viability. On day 5, the cells were washed and used for studies. In some experiments, the cells were stained with Ab to cell surface and intracellular markers and analyzed by flow cytometry. For cell sorting, the cells were stained with anti-CD8, and anti-CD25 mAb (BD Pharmingen, Franklin Lakes, NJ, USA), and sorted as CD8+CD25+ and CD8+CD25−, or as a whole CD8+(CD25−) population from control cultures using a FACSAria cell sorter (BD Biosciences). In some experiments, CD8+ T cells were sorted based on the expression of TNFR2 (CD120b, BD Pharmingen) and CD25.
Autologous or allogeneic PBMC were depleted of CD8+ T cells using Dynabeads CD8 (Invitrogen), labeled with CFSE (Cell Trace Kit, Invitrogen), and used as responding cells in inhibitory assays. Responder cells and sorted CD8+ T cells (105 each per well) were incubated in the presence of SEB (1 μg/mL, Sigma) in AIM-V medium for 72 h and the dilution of CFSE was analyzed by FACS. The percent divided cells were analyzed using the FlowJo software (TreeStar, Ashland, OR, USA), and inhibition of proliferation was calculated as (1−(%divided with added cells/%divided without added cells))×100. For inhibitory assays, using samples from patients in clinical studies, we compared proliferation of allogeneic CD8-depleted cells with CD8+ T cells isolated by magnetic beads before and after treatment with anti-CD3 mAb. The % inhibition was calculated as (1−(%divided with added CD8+ cells from day 14/%divided with added CD8+ cells from day 0))×100.
Neutralizing cytokines with mAb
The following neutralizing Ab were used at a concentration 50 μg/mL: anti-IFN-γ, anti-IL-10, anti-IL10 receptor (CDw210), anti-TNF, and anti-FasL (BD Biosciences); anti-CCL4 (Sigma); anti-PD-1, anti-TGF-β1 (R&D Systems, Minneapolis, MN, USA). Target cells activated by SEB in the presence of each neutralizing mAb served as controls. The effect of the blocking Ab was expressed as the difference in % inhibition by activated or control CD8+ T cells with and without addition of the blocking Ab. Blockade of TNF during induction of CD8+ Treg by anti-CD3 mAb was performed using neutralizing mAb MAb11 (BD Biosciences) or, with Infliximab (Remicade, Centocor, Malvern, PA, USA), both at 80 μg/mL.
Apoptosis and necrosis assays
These studies were performed on day 3 after SEB stimulation of CD8-depleted targets cultured with or without sorted CD8+ Treg or control CD8+ cells. Gated CD4+ T cells were analyzed by flow cytometry using Vybrant® Apoptosis Assay Kit ♯4 (Molecular Probes, Eugene, OR, USA) with YO-PRO®-1 stain for apoptotic and propidium iodide for necrotic cell discrimination. Since the CFSE stain emits in the same channel as YO stain, so we could not measure both in the same cells, but ran parallel wells with CFSE-labeled targets to ensure the integrity of the experiment.
Cell cycle analysis
Proliferation of CD4+ responders was determined using 7-Aminoactinomycin D and anti-Ki-67-FITC (BD Biosciences). After coculture with activated CD8+ T cells, CD4+ cells were isolated using Dynabeads® Untouched Human CD4 T cells Kit (Invitrogen Dynal, Oslo, Norway), fixed and RNA removed by treatment with RNAse A (Sigma) prior to addition of 7-Aminoactinomycin D. Gated Ki-67+ cells were analyzed for DNA content using FlowJo Cell Cycle platform.
Flow cytometry and intracellular staining
Cells were activated with SEB or PMA/ionomycin, treated with monensin, and stained for surface markers followed by fixation, permeabilization, and incubation with anti-cytokine mAb (BD Biosciences) and anti-Foxp3 (eBioscience). To confirm that monensin did not inhibit iCD8+ Treg, CD4+ cells were stained for secreted TNF using TNF Secretion Assay Detection Kit (Miltenyi Biotec, Auburn, CA, USA). Anti-GITR and anti-CTLA-4 mAb were from BD Biosciences.
Statistical analysis was performed using GraphPad Prizm® Version 4 software (GraphPad Software, San Diego, CA, USA). Unless indicated, the data are presented as the mean±SEM. One way ANOVA with Dunnett's or Bonferroni multiple comparison post-tests were used with p<0.05 considered significant. Where indicated, single-column statistics, paired t-test, Mann–Whitney, and Fisher exact tests were used.
This work was supported by NIH grants DK057846 and UL1 RR024139, grants 2006-351, 2006-502, 2007-1059, and grant 2005-1168 from the Juvenile Diabetes Research Foundation, and a gift from the Brehm foundation. The authors are thankful to Paula Preston-Hulburt for technical assistance, Jeffrey Lyon for expert cell sorting, and Lesley Devine from Immune Monitoring Core Facility at Yale Cancer Center for her help with patients' samples.
Conflicts of interest: The authors declare no financial or commercial conflict of interest.